All In Biotech

Drug Trial Radar · NCT06958692

A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Adult Patients With Major Depressive Disorder

Last checked: Nov 19, 2026Latest source record: May 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 388 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

388

Planned (sponsor's estimate)

Start

Apr 11, 2025

Primary completion

Sep 30, 2026

Study completion Dec 30, 2026

Sponsor

Sponsor type
Industry
First posted
May 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial, aim to evaluate the efficacy and safety of dextromethorphan and bupropion sustained-release tablets in Chinese adult patients with major depressive disorder.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

  • Dextromethorphan and Bupropion Sustained-Release TabletsDrug

    Oral dextromethorphan and bupropion sustained-release tablets, taken daily for 6 weeks.

  • PlaceboDrug

    Oral placebo tablets, taken daily for 6 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in MADRS Total Score From Baseline to Week 6Time frame: 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Anding Hospital Affiliated to Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.